Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Clinicogenetic aspects of carbohydrate metabolism disorders and efficacy of their correction with moxonidine and metformine in patients with arterial hypertension].

Terapevticheskii arkhiv - 1 Jan 2005

Kobalava Zh D, Tolkacheva V V, Ignat'ev I V, Glezer M G, Kuzin A I, Karpov Iu A, Konradi A O, Zheleznykh E A

Abstract excerpt

AIM: To study effects of monotherapy with moxonidine and metformine on metabolic parameters in hypertensive patients with carbohydrate dysbolism (CD) regarding polymorphic markers of genes PPARalpha, PPARgamma and IRS type 1 and 2. MATERIAL AND METHODS: A total of 83 patients (31 male and 52 female patients aged 40-75 years) with untreated arterial hypertension stage I, obesity and CD (by glucose tolerance test)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antihypertensive Agents
Share to Carbohydrate Metabolism

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hypoglycemic Agents

Share to Imidazoles

Share to Insulin Receptor Substrate Proteins

Share to Metformin

Share to PPAR alpha

Share to PPAR gamma

Source

Identifiers

PMID: 15759454

Genes

PPARA
IRS1
IRS2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Clinicogenetic aspects of carbohydrate metabolism disorders and efficacy of their correction with moxonidine and metformine in patients with arterial hypertension].PMID 15759454Read ↗

[Influence of polymorphism pro12Ala of PPARgamma gene on endothelium destruction in patients with diabetes mellitus t. 2].Semantic proximity Read ↗

[Molecularly-genetic aspects of metabolic syndrome].Semantic proximity Read ↗

[Pharmacogenetic features of the effect of metformin in patients with coronary heart disease in the presence of metabolic syndrome and type 2 diabetes mellitus in terms of PPAR-gamma2 gene polymorphism].Semantic proximity Read ↗

[Effect of gene polymorphism of PPARgamma2 regulatory proteins on the metabolic syndrome in children with nonalcoholic fatty liver disease and obesity].Semantic proximity Read ↗

[Pharmacogenetics of oral antidiabetic treatment].Semantic proximity Read ↗

[Prevalence of dyslipidemia and its phenotypes in recently diagnosed essential arterial hypertension].Semantic proximity Read ↗

[Pharmacogenetic approaches to predicting the efficiency and safety of amlodipine in patients with arterial hypertension].Semantic proximity Read ↗

[PPARdelta + 294T/C gene polymorphism related to plasma lipid, obesity and left ventricular hypertrophy in subjects with metabolic syndrome].Semantic proximity Read ↗

[Pharmacogenetic aspects of candesartan application for the treatment of arterial hypertension in patients with chronic pyelonephritis].Semantic proximity Read ↗

Investigating the synergistic effects of Telmisartan and Amlodipine with Metformin in patients with metabolic syndromeSemantic proximity Read ↗

Impact of renin-angiotensin-aldosterone system genes on the treatment response of patients with hypertension and metabolic syndrome.Semantic proximity Read ↗

[Effect of hydroxylation polymorphism on the concentration of propranolol in the blood of humans with hyperlipidemia].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.